SCR-LIP-000401 · Claim · machine-readable JSON →
In a cohort of 50 women with confirmed lipedema undergoing tumescent liposuction, quantitative ultrasound elastography (QUS) and B-mode ultrasonography were used to measure postoperative tissue stiffness (e.g., 14.8 ± 3.1 kPa) and fibrotic changes, though the study evaluated serrapeptase efficacy rather than diagnosis.
Claim at a glance
- Type
- clinical association
- Knowledge state
- Emerging
- Evidence certainty
- low (GRADE)
- Evidence
- 1 source(s)
- Answers
- 1 question(s)
- Dates
- 2026-06-14 → 2026-06-14
Structured evidence, machine-compiled — not a verdict.
Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-06-14
Evidence over time
Evidence (1)
- Serrapeptase After Liposuction for Lipedema: Limited Evidence for Antifibrotic Efficacy. — Bruno A, Saccoccio V. (2026) ✓ verified — contextual · cohort · 2026 · reading confidence: high
“The primary outcome was tissue stiffness measured by quantitative ultrasound elastography (QUS). Secondary outcomes included B-mode ultrasonography, patient-reported pain (VAS), and clinical assessment of induration.”
The article uses ultrasound (QUS and B-mode) to assess postoperative tissue stiffness/fibrosis in lipedema patients, but does not test ultrasound's ability to diagnose or classify lipedema itself; it studies serrapeptase efficacy, making it
Context (PECO)
Answers these questions
Gaps & caveats
Auto-ingested single source; not yet human-reviewed.
Change log
- 2026-06-14 — created · auto-ingested for SQ-LIP-000003